

Cytotoxic Screening and In Vitro Evaluation of Pentadecane Against *Leishmania infantum* Promastigotes and Amastigotes

Authors: Bruno, Federica, Castelli, Germano, Migliazzo, Antonella, Piazza, Maria, Galante, Antonella, et al.

Source: Journal of Parasitology, 101(6) : 701-705

Published By: American Society of Parasitologists

URL: <https://doi.org/10.1645/15-736>

BioOne Complete (complete.BioOne.org) is a full-text database of 200 subscribed and open-access titles in the biological, ecological, and environmental sciences published by nonprofit societies, associations, museums, institutions, and presses.

Your use of this PDF, the BioOne Complete website, and all posted and associated content indicates your acceptance of BioOne's Terms of Use, available at www.bioone.org/terms-of-use.

Usage of BioOne Complete content is strictly limited to personal, educational, and non - commercial use. Commercial inquiries or rights and permissions requests should be directed to the individual publisher as copyright holder.

BioOne sees sustainable scholarly publishing as an inherently collaborative enterprise connecting authors, nonprofit publishers, academic institutions, research libraries, and research funders in the common goal of maximizing access to critical research.

CYTOTOXIC SCREENING AND IN VITRO EVALUATION OF PENTADECANE AGAINST *LEISHMANIA INFANTUM* PROMASTIGOTES AND AMASTIGOTES

Federica Bruno, Germano Castelli, Antonella Migliazzo, Maria Piazza, Antonella Galante, Vincenza Lo Verde, Simona Calderone, Giuseppa Nucatolo, and Fabrizio Vitale

Centro di Referenza Nazionale per le Leishmaniosi (C.Re.Na.L.), Istituto Zooprofilattico Sperimentale della Sicilia, Via Gino Marinuzzi 3, 90129, Palermo, Italy. Correspondence should be sent to: biomolecolare@gmail.com

ABSTRACT: Pentadecane is an organic compound that is made up of primarily carbon and hydrogen atoms. Pentadecane is a floral volatile found in many different plants and essential oils and also in crude extracts of some plants, and it shows antimicrobial activity. This study investigated in vitro effects of pentadecane in *Leishmania infantum* parasites and found that it decreases growth by $86 \pm 2\%$ both in promastigotes (half maximal inhibitory concentration [IC₅₀] = 65.3 μ M) and in amastigotes (IC₅₀ = 60.5 μ M), resulting in a reduction of macrophage infection; growth inhibition was 77% at 300 μ M. Analysis of propidium iodide incorporation in *L. infantum*, treated with pentadecane at 48 hr, suggested that cells were arresting in the sub-G0/G1 and G1 phases of the cell cycle, whereas cytotoxicity assay of pentadecane in immortalized cells lines DH82 and U937 and in primary epithelial cells of Cercopiteco showed that it caused negligible cytotoxic effect. This study shows that pentadecane has antimicrobial activity against *L. infantum* parasites in in vitro culture.

Leishmaniasis, caused by the intracellular protozoan *Leishmania infantum* and transmitted by the bite of phlebotomine sand flies, is endemic in 98 countries, with more than 350 million people at risk. Visceral leishmaniasis (VL) caused by parasites of the *Leishmania donovani* complex is a severe human disease that often leads to death if left untreated (World Health Organization, 2010; Maia et al., 2013). Domestic dogs are considered the major host of *Leishmania infantum*, one of the species from the *L. donovani* complex, and this species plays a central role in the transmission cycle to humans by phlebotomine sand flies (Ashford, 2000; Courtenay et al., 2002; Manna et al., 2006). In the absence of effective human and canine vaccines, the only feasible way to treat and control leishmaniasis is through the use of affordable medications. The principal treatment against several forms of leishmaniasis (Fouladvand et al., 2011) is pentavalent antimonials, which are used in much of the world (Croft et al., 2006a; Croft and Olliaro, 2011). In the last decade, significant progress has been made in the development of various formulations of amphotericin B and the oral agent miltefosine for the treatment of VL, although miltefosine is a teratogen and therefore not suitable for women of child-bearing age (World Health Organization, 2010). Liposomal amphotericin B is highly efficient against the disease, with minimum toxicity to the host, and it is currently used as a first-line drug in VL treatment in Europe (Gradoni et al., 2008; Maia et al., 2013). Some of the newer therapies, such as the lipid formulations of amphotericin B, are extremely expensive; this high expense has important implications because, in general, leishmaniasis affects people in the developing world (Meena et al., 2010). These pharmaceutical problems point toward the need to develop new antileishmanial drugs. During the last decade, an increasing interest in the study of organic compounds as chemotherapeutic agents has emerged. Natural products are a potential source of compounds for drug discovery as they contain a large number of molecules, some of which may be bioactive. There have been several reports on the activity of various plant extracts used in herbal medicines against protozoa (Yabu et al.,

1998; Hoet et al., 2004; Aderbauer et al., 2008; Shuaibu et al., 2008).

Pentadecane is an organic compound that is made up primarily of carbon and hydrogen atoms. It is a floral volatile of different plants (El-Baroty et al., 2007; Szmigielski et al., 2012). Previous data demonstrated that a pentadecane derivative inhibits progression of disease in *Leishmania*-infected BALB/c mice (Mbatu et al., 1994). Many essential oils and crude extracts of some plants containing pentadecane have shown an interesting antimicrobial activity (Genovese et al., 2009).

The aim of this study was to analyze and evaluate the in vitro activity and efficacy of pentadecane against *L. infantum* promastigotes and amastigotes. We describe the effects of pentadecane in the cell cycle of *Leishmania* parasites via flow cytometry assay. Finally, to assess the cytotoxic action of pentadecane, a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) viability assay was performed on immortalized cells lines DH82 and U937 and on cultures of primary epithelial cells of Cercopithecus (CPE).

MATERIALS AND METHODS

Parasites

Leishmania infantum promastigotes (MHON/TN/80/IPT1 MON1) received from the Higher Institute of Health, Rome, Italy, were treated in phosphate-buffered saline (PBS) and cultured at 25 C and pH 7.18 in RPMI-PY medium that consisted of RPMI 1640 (R0883, Sigma, St. Louis, Missouri) supplemented with an equal volume of Pepton-yeast medium (Limoncu et al., 1997), 10% fetal bovine serum (FBS, Gibco® RPMI Media 1640, Invitrogen, Carlsbad, California), 1% glutamine, (G6392, Sigma) 250 μ g/ml gentamicin (G3632, Sigma), and 500 μ g/ml of 5-fluorocytosine (F7129, Sigma) (Castelli et al., 2014). Temperature, differentiation time, and acidification of the medium were used as variables for preconditioning of the amastigote cultures. The influence of temperature was evaluated by incubating the promastigotes at 37 C. The conditioning time for the promastigotes varied from 24 to 72 hr and the pH was acidified with 1 N HCl to 5.4 to obtain amastigotes parasites (Da Luz et al., 2009).

Susceptibility assays

Susceptibility of cultures of Leishmania: Flasks containing 5 ml of culture medium were inoculated with 4×10^6 /ml *Leishmania* promastigotes or amastigotes and treated with serial concentrations of pentadecane (50, 100, 150, 200, 250, and 300 μ M). Pentadecane was dissolved in ethanol as recommended by the manufacturer (Sigma) and diluted out in appropriate culture media. After 48 hr of treatment, the percentage of

Received 27 January 2015; revised 25 August 2015; accepted 25 August 2015.

DOI: 10.1645/15-736

vitality of *Leishmania* was observed by counting in a Bürker hemocytometer (VWR International, Albertslund, Denmark) and compared with that of the control culture (100% viability).

Susceptibility of intracellular amastigote-infected macrophages: Macrophages (5×10^5 cells/ml) derived from human Caucasian histiocytic lymphoma U937 cell line (ECACC 85011440, European Collection of Cell Cultures, Porton Down, U.K.) in the logarithmic phase of growth were incubated in 2-chamber Lab-Tek culture slides (Sigma) in 2.5 ml of RPMI 1640 (Sigma) plus 10% fetal calf serum medium (complete RPMI) containing 25 ng/ml phorbol 12-myristate 13-acetate (PMA, Sigma) for 18 hr to induce differentiation (Maia et al., 2007, 2013). After 18 hr, the U937 cell line differentiated into non-dividing adherent cells, and medium containing PMA was removed by washing with RPMI 1640. The medium was removed and cells were resuspended with 2.5 ml of complete RPMI containing promastigotes (stationary phase) of *L. infantum* at a 5:1 parasite:macrophage ratio. The cultures were incubated at 37 C in 5% CO₂-95% ambient air for 24 hr and then washed with PBS (pH 7.2) twice. Infected U937 cells were washed three times with fresh medium before addition of the serial dilutions of the different drugs. Cytotoxicity of each studied drug for U937 cells was determined as described previously (Maia et al., 2007, 2013). In brief, maximum tolerated dose was 300 µM pentadecane.

After 48 hr of incubation, cells were washed with PBS twice, fixed with methanol, and stained with acridine orange (100 µg/ml)-ethidium bromide (100 µg/ml). The number of cells infected was determined by examining 3 coverslips for each treatment. At least 100 macrophages were counted by visual examination under $\times 40$ magnification by using a DM 4000B fluorescence microscope (Leica, Heerbrugg, Switzerland). Results are expressed as percentage of reduction in macrophages infection: reduction in macrophages infection (%) = percentage of infected macrophages of treated macrophages/percentage of infected macrophages of control).

Evaluation of live and dead *L. infantum*: To evaluate the leishmanicidal activity of pentadecane, the percentage of live and dead parasites was determined morphologically after labeling with acridine orange (100 µg/ml) and ethidium bromide (100 µg/ml). After 48 hr of exposure to each compound, parasites (1×10^6) were centrifuged, and the pellet was resuspended in 25 µl of the dye mixture. Ten microliters of the mixture was examined in oil immersion with the $\times 100$ objective of an Eclipse E200 fluorescence microscope (Nikon, Amstelveen, The Netherlands). Live parasites were determined by the uptake of acridine orange (green fluorescence) and exclusion of ethidium bromide (red fluorescence). Dead parasites were determined by the uptake of ethidium bromide (red fluorescence). The percentage of parasite viability was determined after counting at least 300 parasites (Tolomeo et al., 2013).

Flow cytometry analysis of cell cycle: Promastigotes of *L. infantum* were incubated for 24 hr with pentadecane at 26 C. Afterward, the parasites were washed 3 times with PBS containing 0.02 M EDTA to avoid clumps and were then fixed with cold methanol for 24 hr. The parasites were resuspended in 0.5 ml of PBS containing RNase I (50 µg/ml) and propidium iodide (PI) (25 µg/ml) and were then incubated at 25 C for 20 min. The material was kept on ice until analysis. The stained parasites were analyzed in single-parameter frequency histograms by using a FACScan flow cytometer (BD Biosciences, San Jose, California) (Tolomeo et al., 2013).

Cytotoxicity assessment via MTT viability assay: Potential cytotoxic action of the pentadecane was checked via MTT viability assay in DH82 and U937 immortalized cells lines (Carmichael et al., 1987) and in CPE primary epithelial cells. DH82 cells (CRL-10389, American Type Culture Collection, Manassas, Virginia) were propagated in minimum essential medium (MEM) with nonessential amino acids, 2 mM L-glutamine, and 10% FBS (MEM growth media). Cells were grown at 37 C in 5% CO₂ and passaged semiweekly.

U937 cells (ECACC 85011440, European Collection of Cell Cultures) were propagated in RPMI 1640 (R0883, Sigma) plus 10% FBS with 50 ng/ml PMA (Sigma) for 48 hr to induce differentiation (Maia et al., 2007). Cells were grown at 37 C in 5% CO₂ and passaged semiweekly. CPE cells were cultured in RPMI 1640 (R0883, Sigma) supplemented with 10% FBS (Gibco RPMI Media 1640, Invitrogen), penicillin (100 IU/ml, P3032, Sigma), and streptomycin (100 mg/ml, S9137, Sigma). In each experiment, exponentially growing cells were plated in 100-µl aliquots of growth medium into 96-well plates at 10^5 cells per well and then incubated for 24 hr. The cells in the 96-well plates were incubated with pentadecane at concentrations of 50, 150, 200, 250, and 300 µM. After 48 hr of




FIGURE 1. Effects of pentadecane on viability of *Leishmania infantum*. *Leishmania* cultures were incubated with different concentrations of pentadecane for 48 hr. The percentage of viability of *L. infantum* promastigotes and amastigotes was calculated by defining the viability of cells without pentadecane treatment as 100%. Data are the results of 3 independent experiments and are presented as the mean \pm SD. Data obtained are statistically significant at $P < 0.001$.

incubation, MTT solution (5 mg/ml) was added to each well, and the formazan precipitate was dissolved in 100 µl of dimethyl sulfoxide after 4 hr of incubation (Kong et al., 2009). The absorbance was measured using a Spectrostar Nano microplate reader (BMG Labtech Inc., Ortenberg, Germany) at 570 nm.

Statistical analysis

All experiments were performed by 2 observers in 3 replicates and repeated with 3 new batches of parasites. The mean and SE of at least 3 experiments were determined. The differences between the mean values obtained for experimental groups were evaluated by Student's *t*-test. P values ≤ 0.05 are considered significant. The half maximal inhibitory concentration (IC₅₀) values were calculated using Prism® 5 (Version 5.01, GraphPad Software, Inc., San Diego, California).

RESULTS

Antileishmanial activity of pentadecane against promastigotes and amastigotes

Pentadecane was evaluated for anti-leishmania activity against promastigotes and amastigotes of *L. infantum* IPT1 strain. Parasites were incubated with different concentrations of pentadecane, and the *L. infantum* viability was compared to that of the control after incubation for 48 hr (see Materials and Methods).

Controls containing the equivalent concentrations of ethanol to those in different pentadecane doses were included and showed no adverse effect on *L. infantum* viability (data not shown). Pentadecane showed anti-*L. infantum* activity in a dose-dependent manner: at 50, 100, 150, 200, 250, and 300 µM, it reduced parasite viability by 63, 33, 20, 18, 17, and 13%, respectively, for promastigotes and by 64, 30, 18, 16, 14, and 13% for amastigotes. The concentration that caused 50% reduction in survival in comparison to the control was estimated by Prism to be 60.5 µM for *L. infantum* amastigotes and 65.3 µM for *L. infantum* promastigotes (Fig. 1).




FIGURE 2. Leishmanicidal activity of pentadecane. Morphological changes observed in *Leishmania infantum* after exposure to pentadecane. Cells were exposed to a mixture of acridine orange and ethidium bromide as described in Materials and Methods. Live parasites were determined by the uptake of acridine orange (green fluorescence) and exclusion of ethidium bromide (red fluorescence). Dead parasites were determined by the uptake of ethidium bromide (red fluorescence). (A) Control. (B) Promastigotes exposed to 65.3 μM pentadecane for 48 hr. (C, D) Promastigotes exposed to 300 μM pentadecane for 48 hr. Parasites take up ethidium bromide, showing a loss of volume and nuclear condensation. Color version available online.

Leishmanicidal activity of pentadecane

Leishmania infantum exposed to pentadecane 48 hr and stained with an acridine–ethidium bromide mixture showed changes in morphology (e.g., loss of cell volume and nuclear condensation) that share many characteristics with apoptotic cell death in metazoans (Fig. 2).

Cell cycle: The DNA content of *L. infantum* cells was monitored by flow cytometry after PI staining. When *L. infantum* promastigotes were incubated with 65.3 μM pentadecane for 24 hr, the proportion of cells in the sub-G₀/G₁ phase increased to compare that of the controls (17.41 vs. 7.24%). In contrast, an

increase in the number of cells in the sub-G₀/G₁ phase led to a decrease in the cell number in the G₂/M phase compared with untreated cells (0 vs. 3.2%) (Table I). The increased ratio of cells in the sub-G₀/G₁ phase, after 24 hr, showed that apoptosis via pentadecane in *L. infantum* promastigotes resulted in DNA degradation.

Cytotoxicity of pentadecane: In a first series of experiments, 2 tumorigenic cell lines, dog macrophage DH82 and human lymphoblast U937, and also normal CPE primary epithelial cells were chosen to determine the cytotoxic activity of different concentrations of pentadecane. A vitality higher than 60% was

TABLE I. Cell cycle of *Leishmania infantum* after treatment with 65.3 μM pentadecane for 24 hr.

Group	Proportion of <i>L. infantum</i> cells (%) in cell cycle phase			
	Sub-G0/G1	G1	S	G2/M
Control	7.24	34.24	62.56	3.2
Treated	17.41	39.49	60.51	0

observed (Fig. 3), suggesting a non-toxic action both in immortalized cells (DH82, U937) and in primary cells (CPE).

Antileishmanial activity of pentadecane against intracellular amastigotes: The susceptibility of *Leishmania* parasites (intracellular amastigotes) to pentadecane was determined in 3 individual experiments with 2 replicates. After 48 hr, the percentage of infected macrophages was higher for the control than for the infected macrophages that were treated with pentadecane. The mean number of internalized parasites for macrophages treated with pentadecane was markedly lower than that for the control. Thus, pentadecane showed 50% inhibition of cell survival (IC_{50}) at a concentration of 194.8 μM (Table II), with a growth inhibition of 77% at 300 μM .

DISCUSSION

Although chemotherapy is the only effective treatment for leishmaniasis, the anti-leishmanial drugs available are, in general, toxic, expensive, and require long-term treatment. These side effects and disadvantages demonstrate the necessity to identify new, effective, and safe compounds for the treatment of this disease (Croft et al., 2006b; Rodrigues et al., 2014). The domestic dog is the main reservoir for the transmission of the visceral form of leishmaniasis, thereby accounting for its widespread occurrence in the human population (Courtenay et al., 2002). At present, leishmaniasis is an incurable and complex zoonosis, whose true incidence is not known and, for ethical reasons, drastic measures (e.g., stamping-out) are not to be proposed for animal health. Furthermore, there is a large difference between the immuno-




FIGURE 3. Effects of pentadecane on DH82 and U937 cell lines and primary epidermal cells of CPE. The cells were exposed to the indicated concentrations of pentadecane for 48 hr, and then cell viability was monitored by MTT assay.

TABLE II. IC_{50} values for growth inhibition assays (promastigote and amastigote cultures and intracellular amastigotes).

Life stage	IC_{50} (μM) of pentadecane in <i>L. infantum</i>
Promastigote	63.5 \pm 0.5
Amastigote	60.5 \pm 0.6
Intracellular amastigote	194.8 \pm 0.6

competent patients, who are healed completely after treatment, and patients in which recurrence is a regular occurrence regardless of the drug treatment. The current drugs decrease the parasitic charge and promote the cell-mediated immune response, but they fail to eradicate the disease. Therefore, the development of new therapeutic protocols for the treatment of leishmaniasis and new drugs with leishmanicidal and immunomodulatory activity are needed to achieve the elimination of *L. infantum*. However, it is also necessary to develop economical drugs for developing countries where the impact of leishmaniasis is greatest. In this study, we showed the action of pentadecane as an antileishmanial agent and provided data indicating it did not have a cytotoxic effect in immortalized DH82 and U937 cell lines and in primary cells CPE.

Pentadecane treatment decreased the viability of *L. infantum* promastigotes and amastigotes up to 14% at 300 μM (IC_{50} promastigotes, 65.3 μM ; IC_{50} amastigotes, 60.5 μM). Pentadecane caused a reduction of macrophage infection and its effect on infected macrophages should be of great interest; in fact, pentadecane was even more effective against intracellular amastigotes, with a growth inhibition of 77% for 300 μM after 48 hr of treatment. A cytotoxicity assay of pentadecane in immortalized cells lines DH82 and U937 and in primary epithelial cells of CPE showed that it caused negligible cytotoxic effects.

The DNA content in cells had a direct relationship with the amount of fluorescence intensity and DNA degradation of the cell by apoptosis results into PI intensity lower G1 cells (sub-G1 peak). *Leishmania infantum* promastigotes exposed to 24 hr with 65.3 μM pentadecane increased 17% cells proportion in the sub-G1 peak region, whereas in the control only 7% were found in this region. Furthermore, *L. promastigotes* treated with 65.3 μM pentadecane for 24 hr induced DNA degradation.

This selectivity assay showed that the action of pentadecane is specific for protozoans and is not toxic for mammalian cells. This study shows a potent leishmanicidal activity of pentadecane that may provide promising treatment options against leishmaniasis. The mechanism of action of pentadecane is currently unknown, but is the subject of intense investigation in our laboratory. A better understanding of the mechanisms of pentadecane action may help in finding new targets for the treatment of *Leishmania* parasites. Further studies are required to evaluate whether pentadecane can be used as single anti-leishmanial compound or as a fortifying agent with existing synthetic compounds for the development of anti-leishmanial agents.

ACKNOWLEDGMENT

This research was funded by Ministry of Health project "IZS SI 13 / 2012 RC - Nuovi approcci terapeutici per la terapia della infezione da *Leishmania infantum*: il ruolo di composti naturali, stilbenici, terfenilici e valutazioni *in vitro* e *in vivo*".

LITERATURE CITED

- ADERBAUER, B., P. H. CLAUSEN, O. KERSHAW, AND M. F. MELZIG. 2008. *In vitro* and *in vivo* trypanocidal effect of lipophilic extracts of medicinal plants from Mali and Burkina Faso. *Journal of Ethnopharmacology* **119**: 225–231.
- ASHFORD, R. W. 2000. The leishmaniasis as emerging and reemerging zoonoses. *International Journal for Parasitology* **30**: 1269–1281.
- CARMICHAEL, J., W. G. DEGRAFF, A. F. GAZDAR, J. D. MINNA, AND J. B. MITCHELL. 1987. Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of radiosensitivity. *Cancer Research* **47**: 943–946.
- CASTELLI, G., A. GALANTE, V. LO VERDE, A. MIGLIAZZO, S. REALE, T. LUPO, M. PIAZZA, F. VITALE, AND F. BRUNO. 2014. Evaluation of two modified culture media for *Leishmania infantum* cultivation versus different culture media. *Journal of Parasitology* **100**: 228–230.
- COURTENAY, O., R. J. QUINNELL, L. M. GARCEZ, AND C. DYE. 2002. Low infectiousness of a wildlife host of *Leishmania infantum*: The crabeating fox is not important for transmission. *Parasitology* **125**: 407–414.
- CROFT, S. L., AND P. OLLIARO. 2011. Leishmaniasis chemotherapy—Challenges and opportunities. *Journal of Clinical Immunology* **17**: 1478–1483.
- , K. SEIFERT, AND V. YARDLEY. 2006a. Current scenario of drug development for leishmaniasis. *Indian Journal of Medical Research* **123**: 399–410.
- , S. SUNDAR, AND A. H. FAIRLAMB. 2006b. Drug resistance in leishmaniasis. *Clinical Microbiology Reviews* **19**: 111–126.
- DA LUZ, R. I., M. VERMEERSCH, J. C. DUJARDIN, P. COS, AND L. MAES. 2009. *In vitro* sensitivity testing of *Leishmania* clinical field isolates: Preconditioning of promastigotes enhances infectivity for macrophage host cells. *Antimicrobial Agents and Chemotherapy* **53**: 5197–5203.
- EL-BAROTY, G. S., M. Y. MOUSSA, M. A. SHALLAN, M. A. ALI, A. Z. SABH, AND E. A. SHALABY. 2007. Contribution to the aroma, biological activities, minerals, protein, pigments and lipid contents of the red alga: *Asparagopsis taxiformis* (Delile) Trevisan. *Journal of Applied Sciences Research* **3**: 1825–1834.
- FOULADVAND, M., A. BARAZESH, F. FAROKHZAD, H. MALEKIZADEH, AND K. SARTAVI. 2011. Evaluation of *in vitro* anti-leishmanial activity of some brown, green and red algae from the Persian Gulf. *European Review for Medical and Pharmacological Sciences* **15**: 597–600.
- GENOVESE, G., L. TEDONE, M. T. HAMANN, AND M. MORABITO. 2009. The Mediterranean red alga *Asparagopsis*: A source of compounds against *Leishmania*. *Marine Drugs* **7**: 361–366.
- GRADONI, L., K. SOTERIADOU, H. LOUZIR, A. DAKKAK, S. O. TOZ, C. JAFFE, J. P. DEDET, L. CAMPINO, C. CAÑAVATE, AND J. C. DUJARDIN. 2008. Drug regimens for visceral leishmaniasis in Mediterranean countries. *Tropical Medicine and International Health* **13**: 1272–1276.
- HOET, S., F. OPPERDOES, R. BRUN, V. ADJAKIDJÉ, AND J. QUÉLIN-LECLERCQ. 2004. *In vitro* antitrypanosomal activity of ethnopharmacologically selected Beninese plants. *Journal of Ethnopharmacology* **91**: 37–42.
- KONG, Y., W. MA, X. LIU, Y. ZU, Y. FU, N. WU, L. LIANG, L. YAO, AND T. EFFERTH. 2009. Cytotoxic activity of curcumin towards CCRF-CEM leukemia cells and its effect on DNA damage. *Molecules* **14**: 5328–5338.
- LIMONCU, M. E., I. C. BALCIOĞLU, K. YERELI, Y. OZBEL, AND A. OZBILGIN. 1997. A new experimental *in vitro* culture medium for cultivation of *Leishmania* species. *Journal of Clinical Microbiology* **35**: 2430–2431.
- MAIA, C., M. NUNES, M. MARQUES, S. HENRIQUES, N. ROLÃO, AND L. CAMPINO. 2013. *In vitro* drug susceptibility of *Leishmania infantum* isolated from humans and dogs. *Experimental Parasitology* **135**: 36–41.
- , N. ROLÃO, M. NUNES, L. GONÇALVES, AND L. CAMPINO. 2007. Infectivity of five different types of macrophages by *Leishmania infantum*. *Acta Tropica* **90**: 123–126.
- MANNA, L., S. REALE, E. VIOLA, F. VITALE, V. FOGLIA MANZILLO, L. M. PAVONE, S. CARACAPPA, AND A. E. GRAVINO. 2006. *Leishmania* DNA load and cytokine expression levels in asymptomatic naturally infected dogs. *Veterinary Parasitology* **142**: 271–280.
- MBATI, P. A., K. ABOK, A. S. ORAGO, C. O. ANJILI, J. M. KAGAI, J. I. GITHURE, AND D. K. KOECH. 1994. Pristane (2,6,10,14-Tetramethylpentadecane) inhibits disease progression in *Leishmania*-infected Balb/c mice. *African Health Sciences* **1**: 157–159.
- MEENA, A. K., P. BANSAL, S. KUMAR, M. M. RAO, AND V. K. GARG. 2010. Estimation of heavy metals in commonly used medicinal plants: A market basket survey. *Environmental Monitoring and Assessment* **170**: 657–660.
- RODRIGUES, A. P., L. H. FARIAS, A. S. CARVALHO, A. S. SANTOS, J. L. DO NASCIMENTO, AND E. O. SILVA. 2014. A novel function for kojic acid, a secondary metabolite from *Aspergillus* fungi, as antileishmanial agent. *PLoS One* **9**: e91259.
- SHUAIBU, M. N., K. PANDEY, P. A. WUYEP, T. YANAGI, K. HIRAYAMA, A. ICHINOSE, T. TANAKA, AND I. KOUNO. 2008. Castalagin from *Anogeissus leiocarpus* mediates the killing of *Leishmania in vitro*. *Parasitology Research* **103**: 1333–1338.
- SZMIGIELSKI, R., M. CIESLAK, K. J. RUDZIŃSKI, AND B. MACIEJEWSKA. 2012. Identification of volatiles from *Pinus silvestris* attractive for *Monochamus galloprovincialis* using a SPME-GC/MS platform. *Environmental Science and Pollution Research* **19**: 2860–2869.
- TOLOMEO, M., M. ROBERTI, L. SCAPOZZA, C. TARANTELLI, E. GIACOMINI, L. TITONE, L. SAPORITO, P. DI CARLO, AND C. COLOMBA. 2013. TTAS a new stilbene derivative that induces apoptosis in *Leishmania infantum*. *Experimental Parasitology* **133**: 37–43.
- WORLD HEALTH ORGANIZATION. 2010. Control of the leishmaniasis. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniasis, 22–26 March 2010. WHO Technical Report Series 949. World Health Organization, Geneva, Switzerland, 186 p.
- YABU, Y., M. NOSE, T. KOIDE, N. OHTA, AND Y. OGIHARA. 1998. Antitrypanosomal effects of traditional Chinese herbal medicines on bloodstream forms of *Trypanosoma brucei rhodesiense in vitro*. *Southeast Asian Journal of Tropical Medicine and Public Health* **29**: 599–604.